Dance Biopharm Holdings, Inc.

News and Events

Latest Release

Jun 8, 2019 • 1:00 EDT

Dance Biopharm Presents Encouraging Data from Phase 2 Clinical Trial of Dance 501 Inhaled Insulin Therapy at American Diabetes Association Meeting

- Faster onset of action shown for Dance 501 compared to subcutaneous injection of insulin lispro – - No changes in lung function and no cough observed in patients